Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1801
PUT
Datadog
DDOG
$66.5B
| $7.7M | ﹤0.01% |
28,100
-46,900
| -63% | -$11.6M |
2024 Q3
8 quarters
|
|
1802
Alignment Healthcare
ALHC
$1.54B
| $7.67M | ﹤0.01% |
940,243
+835,162
| +795% | +$12.5M |
2022 Q1
18 quarters
|
|
1803
Marcus Corp
MCS
$838M
| $7.66M | ﹤0.01% |
274,816
+5,462
| +2% | +$148K |
2016 Q1
42 quarters
|
|
1804
Figma
FIG
$10.4B
| $7.66M | ﹤0.01% |
364,423
-1,174,625
| -76% | -$28.1M |
2025 Q3
4 quarters
|
|
1805
Oxford Lane Capital
OXLC
$494M
| $7.66M | ﹤0.01% |
850,002
| – | – |
2025 Q4
3 quarters
|
|
1806
Selective Insurance
SIGI
$6.12B
| $7.64M | ﹤0.01% |
91,341
+75,521
| +477% | +$7.01M |
2016 Q1
42 quarters
|
|
1807
Thor Industries
THO
$3.99B
| $7.63M | ﹤0.01% |
110,419
+10,839
| +11% | +$817K |
2013 Q2
53 quarters
|
|
1808
Skywest
SKYW
$3.13B
| $7.62M | ﹤0.01% |
78,609
+9,427
| +14% | +$955K |
2016 Q2
41 quarters
|
|
1809
Cavco Industries
CVCO
$4.92B
| $7.62M | ﹤0.01% |
13,596
-1,819
| -12% | -$1.03M |
2016 Q1
42 quarters
|
|
1810
Valaris
VAL
$5.84B
| $7.57M | ﹤0.01% |
96,350
+65,647
| +214% | +$5.35M |
2022 Q1
18 quarters
|
|
1811
Haemonetics
HAE
$5.6B
| $7.55M | ﹤0.01% |
71,684
+35,485
| +98% | +$3.3M |
2013 Q2
53 quarters
|
|
1812
Caris Life Sciences
CAI
$6.61B
| $7.52M | ﹤0.01% |
245,611
+204,383
| +496% | +$4.59M |
2025 Q2
5 quarters
|
|
1813
StepStone Group
STEP
$3.95B
| $7.52M | ﹤0.01% |
173,160
-35,858
| -17% | -$1.67M |
2022 Q1
18 quarters
|
|
1814
PUT
Danaher
DHR
$164B
| $7.51M | ﹤0.01% |
+33,900
| New | +$6.96M |
2026 Q3
0 quarters
|
|
1815
CALL
AbbVie
ABBV
$521B
| $7.51M | ﹤0.01% |
28,700
-1,300
| -4% | -$333K |
2023 Q4
11 quarters
|
|
1816
China Yuchai International
CYD
$816M
| $7.5M | ﹤0.01% |
241,857
+835
| +0.3% | +$34.7K |
2025 Q1
6 quarters
|
|
1817
PUT
Newmont
NEM
$118B
| $7.5M | ﹤0.01% |
65,000
| – | – |
2024 Q3
8 quarters
|
|
1818
TAL Education Group
TAL
$5.7B
| $7.49M | ﹤0.01% |
620,533
-722,179
| -54% | -$8.23M |
2015 Q4
43 quarters
|
|
1819
Ingram Micro Holding
INGM
$6.51B
| $7.48M | ﹤0.01% |
279,034
-166,369
| -37% | -$4.66M |
2024 Q4
7 quarters
|
|
1820
CALL
Hims & Hers Health
HIMS
$4.62B
| $7.45M | ﹤0.01% |
250,000
| – | – |
2025 Q1
6 quarters
|
|
1821
BeOne Medicines Ltd
ONC
$47.6B
| $7.44M | ﹤0.01% |
20,335
-7,381
| -27% | -$2.52M |
2016 Q4
39 quarters
|
|
1822
FuelCell Energy
FCEL
$774M
| $7.42M | ﹤0.01% |
452,127
+417,498
| +1,206% | +$8.21M |
2019 Q4
27 quarters
|
|
1823
Dana Inc
DAN
$2.39B
| $7.42M | ﹤0.01% |
271,607
-13,497
| -5% | -$388K |
2013 Q2
53 quarters
|
|
1824
Mattel
MAT
$4.32B
| $7.4M | ﹤0.01% |
584,673
+242,580
| +71% | +$3.44M |
2013 Q2
53 quarters
|
|
1825
CALL
Dianthus Therapeutics
DNTH
$5.17B
| $7.39M | ﹤0.01% |
+83,900
| New | +$8.71M |
2026 Q3
0 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.